vialroom

#retatrutide 2025-12-26

Friday18 messages5 participantstimes are UTC
Highlights from this day
  • tarpit_tam — no idea whether the heart rate settles for everyone, mine did and one log isnt data, n of 1 obviously 14:30
  • tarpit_tam — the honest position is this has less human evidence behind it than anything else discussed here 15:24
  • c18_column — anyone compared their Janoshik purity across two different HJ lots 15:34
  • c18_column — slightly off topic but TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule 15:38

why does everyone insist on smaller steps here than on the other two

logging rhr daily

the half life supports weekly dosing and thats what ive done from the start

TT

blood pressure stayed flat for me while heart rate moved, which i didnt expect, we shall see

TT

no idea whether the heart rate settles for everyone, mine did and one log isnt data, n of 1 obviously

C1

update on the earlier thing anyone logging resting heart rate on this

triple agonist yeah

VI

is there any long term safety data at all or is it phase 2 and hope

RR

my resting rate went up 8 bpm in the first month and came back most of the way by month 13

TT

the honest position is this has less human evidence behind it than anything else discussed here

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
C1

anyone compared their Janoshik purity across two different HJ lots

is the phase 2 dosing anywhere near what people here run

slightly off topic but TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule